A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
Public ClinicalTrials.gov record NCT04580771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer
Study identification
- NCT ID
- NCT04580771
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 22 participants
Conditions and interventions
Conditions
- Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Stage IB3 Cervical Cancer FIGO 2018
- Stage II Cervical Cancer FIGO 2018
- Stage IIA Cervical Cancer FIGO 2018
- Stage IIA1 Cervical Cancer FIGO 2018
- Stage IIA2 Cervical Cancer FIGO 2018
- Stage IIB Cervical Cancer FIGO 2018
- Stage III Cervical Cancer FIGO 2018
- Stage IIIA Cervical Cancer FIGO 2018
- Stage IIIB Cervical Cancer FIGO 2018
- Stage IIIC Cervical Cancer FIGO 2018
- Stage IIIC1 Cervical Cancer FIGO 2018
- Stage IIIC2 Cervical Cancer FIGO 2018
- Stage IVA Cervical Cancer FIGO 2018
Interventions
- Cisplatin Drug
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 Biological
- Radiation Therapy Radiation
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2020
- Primary completion
- Mar 7, 2027
- Completion
- Mar 7, 2027
- Last update posted
- Apr 14, 2026
2020 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04580771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04580771 live on ClinicalTrials.gov.